President Donald Trump signed an executive order on April 18, 2026, directing the FDA to issue research guidance on ibogaine, a Schedule I substance prohibited in the U.S. but used abroad for conditions like PTSD, depression, and anxiety, while committing $50 million to federal studies and expanding Right to Try access for desperately ill patients. The order does not reclassify ibogaine and emphasizes treatments in advanced clinical trials. Robert F. Kennedy Jr., confirmed as Health Secretary, was present at related events.